Introduction
HDL-cholesterol efflux capacity (CEC) is increasingly recognized as an important determinant of cardiovascular (CV) risk. 1, 2 Randomized controlled clinical trials with drugs such as niacin or cholesterol ester transport protein inhibitors increased HDL-concentration but did not improve CV outcomes, suggesting that steady-state HDL-concentration alone may not capture the complexity of HDL-associated lipid metabolism and its classically protective role in atherosclerosis. 3 -5 Furthermore, CEC, which estimates HDL's ability to accept cholesterol from peripheral tissues such as macrophages for retrograde transport for excretion into feces, was associated inversely with incident atherosclerotic CV disease recently in a large-scale prospective cohort study 1 independent of circulating HDL-cholesterol concentration, suggesting CEC may better capture the beneficial effect of HDL in atherosclerotic diseases. Psoriasis is a chronic inflammatory skin disease associated with CV events, presumably due to accelerated atherogenesis. 6, 7 Furthermore, CEC is impaired in psoriasis 8 and is recovered after successful psoriasis treatment, 9 suggesting a link between the systemic inflammation observed in psoriasis and impaired HDL function. Therefore, psoriasis serves as an in vivo model to study CEC and its relation to inflammatory atherogenesis. 10 Coronary computed tomography angiography (CCTA) is validated against intravascular ultrasound 11 and provides a reliable framework to understand how emerging biomarkers and biological pathways may relate to in vivo coronary plaque. Coronary computed tomography angiography provides a measure of total coronary plaque burden and can delineate plaque composition. Therefore, the aim of our current investigation was to understand whether CEC relates to coronary plaque burden in psoriasis. We hypothesized that the total burden (TB) of coronary plaque, specifically the non-calcified component, would be inversely related to CEC.
Materials and methods
The study population included 101 consecutive patients recruited for measurement of coronary plaque burden by CCTA as part of a 4-year prospective cohort study of cardiometabolic diseases in psoriasis at the National Institutes of Health (NIH) Clinical Center (NCT01778569). Data presented here are from the baseline visit of this study of the first 101 patients. 12 All patients provided written informed consent, and the study protocol is in compliance with the Declaration of Helsinki. In brief, study participants were .18 years of age with diagnostic confirmation of plaque psoriasis by a dermatologist. Exclusion criteria included pregnancy and lactating women or estimated glomerular filtration rate ,30 mL/min/1.73 m 2 .
Patients underwent CCTA (320-detector row Aquilion ONE ViSION, Toshiba, Japan) and fasting blood draw on the same day. Coronary plaque was separately assessed in each of the main coronary arteries (left anterior descending, left circumflex, and right coronary artery) using QAngio CT (Medis, The Netherlands). Total burden and non-calcified burden (NCB) plaque indices were calculated by dividing total vessel plaque volume by total vessel length ( Figure 1 ).
Cholesterol efflux capacity was measured in duplicate using a validated cell-based ex vivo assay involving the incubation of J774 macrophages with apoB-depleted serum from psoriasis subjects as previously described. 8 Spearman correlation testing, unadjusted, and multivariable linear regression were used to assess the relationship between non-calcified coronary plaque burden and CEC beyond traditional CV risk factors (age, sex, LDL-cholesterol, systolic blood pressure, fasting blood glucose, and tobacco use), HDL, and apoA1 concentrations. Standardized b coefficients are reported. Plaque indices were adjusted for lumen intensity. We also performed stratified analyses, adjusted analyses, and sensitivity analyses to understand whether psoriasis treatment or statin medication modified our primary results. Finally, we tested for interaction by gender in fully adjusted models. All reported P values are two-tailed, with P-value ,0.05 indicating statistical significance.
Results
The study population ( Table 1 ) included 101 psoriasis patients [median psoriasis area severity index (PASI) score 6.2 indicating moderate skin disease severity] with low 10-year pooled cohort equation risk score (median 2.7%). Traditional lipid profiles were within normal limits, and the median CEC was 0.94. We found body mass index (BMI). We found no difference by psoriasis treatment status or statin use, although systemic/biological therapy was associated with reduction in NCB in psoriasis (b 20.11, P ¼ 0.04). Interestingly, this relationship between CEC and NCB was stronger in women compared with men in fully adjusted models (b 20.31; P ¼ 0.001 and b 20.22; P ¼ 0.01 for women and men, respectively) with a statistically significant gender interaction (P , 0.001).
Discussion
Here, we demonstrate that in psoriasis, an inflammatory disease associated with increased atherosclerosis and CV events, poor HDL function is associated with an increased TB of coronary atherosclerosis and non-calcified plaque. This relationship remained significant even after adjustment for traditional CV risk factors, HDL-concentration, apoA1 levels, and BMI and displayed a stronger relationship in women compared with men. To our knowledge, this is the first study to examine the relationship of CEC with characterized coronary plaque burden quantitatively. Our findings in psoriasis are consistent with previous reports demonstrating inverse association between HDL function and subclinical atherosclerosis in non-psoriasis patients. 2 Cholesterol efflux capacity is increasingly recognized as a promising marker of HDL activity, and recently was inversely associated with adverse CV outcomes independent of HDL-concentration. 1 Our finding that non-calcified coronary plaque burden is inversely associated with CEC independent of HDL-concentration supports CEC as an important metric in understanding the relationship between HDL and coronary atherosclerosis. A relationship between CEC and NCB suggests that higher CEC may promote reverse cholesterol transport from earlier, more lipid-rich plaques. Others have found this non-calcified plaque to be the culprit lesions in acute coronary syndromes. 13, 14 Therefore, in the context of our study, there is strong biological plausibility for observing a relationship between CEC and NCB; psoriasis is associated with both increased future CV events and impaired HDL function, and our findings suggest that this may be due to predisposition towards formation of non-calcified plaque.
Our results are in line with report of an inverse association between CEC and carotid intima media thickness and coronary stenosis by coronary angiography. Another study did not find an association between CEC and incident MI, stroke, or MACE. 15 However, in line with our observation, the study did demonstrate that CEC was inversely associated with the risk of prevalent CAD in two cohorts.
Finally, we observed a significant gender interaction whereby women with psoriasis who have lower CEC had higher non-calcified plaque compared with men beyond HDL-C adjustment. Although the mechanism of this interaction remains to be elucidated, these findings may suggest that greater CEC may be more protective against non-calcified plaque in women than it is in men. Despite the cross-sectional nature of this study, ongoing follow-up of these patients will inform whether aggressive treatment of psoriasis and lifestyle measures improve CEC and ultimately non-calcified burden within the coronary arteries in psoriasis. Future studies should focus Cholesterol efflux capacity in psoriasis
